Skip to Content
Merck
  • Energy restriction causes metaphase delay and chromosome mis-segregation in cancer cells.

Energy restriction causes metaphase delay and chromosome mis-segregation in cancer cells.

Cell cycle (Georgetown, Tex.) (2021-05-29)
Aoxing Cheng, Ya Jiang, Ting Wang, Fazhi Yu, Iqra Ishrat, Dongming Zhang, Xiaoyang Ji, Minhua Chen, Weihua Xiao, Qing Li, Kaiguang Zhang, Gang Niu, Jue Shi, Yueyin Pan, Zhenye Yang, Jing Guo
ABSTRACT

ATP metabolism during mitosis needs to be coordinated with numerous energy-demanding activities, especially in cancer cells whose metabolic pathways are reprogramed to sustain rapid proliferation in a nutrient-deficient environment. Although strategies targeting the energy metabolic pathways have shown therapeutic efficacy in preclinical cancer models, how normal cells and cancer cells differentially respond to energy shortage is unclear. In this study, using time-lapse microscopy, we found that cancer cells displayed unique mitotic phenotypes in a dose-dependent manner upon decreasing ATP (i.e. energy) supply. When reduction in ATP concentration was moderate, chromosome movements in mitosis were barely affected, while the metaphase-anaphase transition was significantly prolonged due to reduced tension between the sister-kinetochores, which delayed the satisfaction of the spindle assembly checkpoint. Further reduction in ATP concentration led to a decreased level of Aurora-B at the centromere, resulting in increased chromosome mis-segregation after metaphase delay. In contrast to cancer cells, ATP restriction in non-transformed cells induced cell cycle arrest in interphase, rather than causing mitotic defects. In addition, data mining of cancer patient database showed a correlation between signatures of energy production and chromosomal instability possibly resulted from mitotic defects. Together, these results reveal that energy restriction induces differential responses in normal and cancer cells, with chromosome mis-segregation only observed in cancer cells. This points to targeting energy metabolism as a potentially cancer-selective therapeutic strategy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Reversine, ≥98% (HPLC), solid
Sigma-Aldrich
2-Deoxy-D-glucose, ≥98% (GC), crystalline